Research Library

258 clinical papers on GLP-1 medications. Each with a plain-language summary of the key finding. This is the evidence behind everything we publish.

Landmark Trial · Evidence Grade A

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Lincoff et al. · The New England Journal of Medicine · 2023

Key finding: Semaglutide 2.4mg reduced major cardiovascular events by 20% (HR 0.80) in 17,604 adults with obesity but without diabetes over a median 40 months.

cardiovascular weight-loss semaglutide n=17,604

RCT · Evidence Grade A

Tirzepatide Once Weekly for the Treatment of Obesity

Jastreboff et al. · The New England Journal of Medicine · 2022

Key finding: Tirzepatide at 15mg dose produced 22.5% weight loss at 72 weeks in adults with obesity, with over a third of participants losing 25% or more.

weight-loss tirzepatide SURMOUNT-1

RCT · Evidence Grade A

Two-Year Effects of Semaglutide in Adults with Overweight or Obesity

Garvey et al. · Nature Medicine · 2023

Key finding: Weight loss with semaglutide 2.4mg was sustained over 2 years, with patients maintaining approximately 15% weight loss from baseline.

weight-loss semaglutide long-term

Body Composition · Evidence Grade A

Changes in Body Composition with Semaglutide

Circulation · 2024

Key finding: Approximately 24-39% of total weight lost on semaglutide was lean mass, underscoring the importance of protein intake and resistance training.

body-composition muscle-loss semaglutide

Head-to-Head · Evidence Grade A

Tirzepatide versus Semaglutide: Head-to-Head Comparison

The New England Journal of Medicine · 2025

Key finding: Direct comparison showing tirzepatide producing greater weight loss than semaglutide at equivalent doses, with similar safety profiles.

tirzepatide semaglutide head-to-head

Showing 5 of 258 papers. Full searchable library coming soon.

Research Library

Research updates in your inbox